NewAmsterdam Pharma Company N.V.: Business Overview, Financials & Competitive Analysis
NewAmsterdam Pharma Company N.V. scores 7/10 on the AskCyborg Cyborg Score (Strong). Focused late-stage biotech with first-mover advantage in next-generation CETP inhibition and multi-indication potential, trading at a valuation discount despite strong analyst consensus. Late-stage clinical company with a validated lead asset showing strong regulatory and clinical progress. Consensus analyst support and substantial market cap ($3.94B) indicate institutional confidence, though.
What is NewAmsterdam Pharma Company N.V.'s industry? NewAmsterdam Pharma Company N.V. (newamsterdampharma.com) operates in Biopharmaceutical / Clinical-Stage Drug Development. AskCyborg classifies NewAmsterdam Pharma Company N.V. under Biopharmaceutical / Clinical-Stage Drug Development in its company registry.
NewAmsterdam Pharma is a late-stage biopharmaceutical company developing next-generation therapies for cardiometabolic diseases. The company's lead asset, obicetrapib, is an oral CETP inhibitor positioned to address l...
Cyborg Score thesis
Focused late-stage biotech with first-mover advantage in next-generation CETP inhibition and multi-indication potential, trading...
Read the full analyst-debate transcript →Get the Latest NewAmsterdam Pharma Company N.V. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeNewAmsterdam Pharma Company N.V. Overview
Pro stress-test →NewAmsterdam Pharma is a late-stage biopharmaceutical company developing next-generation therapies for cardiometabolic diseases. The company's lead asset, obicetrapib, is an oral CETP inhibitor positioned to address limitations in current LDL cholesterol-lowering treatments, with clinical trials underway across cardiovascular and neurological indications.
Strategic Profile
Pro stress-test →Trading at approximately 35x earnings multiples with significant upside potential, NewAmsterdam has built a focused pipeline around obicetrapib's mechanism. The company demonstrates strong analyst confidence (12 of 12 buy ratings) and trades substantially below peer valuation estimates, positioning it as a differentiated player in the competitive metabolic disease space.
Competitive Landscape
Pro stress-test →NewAmsterdam competes in the cardiometabolic disease therapeutic space against established players developing CETP inhibitors and other LDL-lowering mechanisms. The company's low-dose oral formulation differentiates it from historical CETP inhibitors, positioning obicetrapib as next-generation therapy addressing unmet needs in statin-resistant populations.
Industry Context
NewAmsterdam Pharma Company N.V. operates in Biopharmaceutical / Clinical-Stage Drug Development.
Key facts
Headquarters: Naarden, Netherlands · Employees: 100 · Revenue: $22.5M · Market cap: $3.94B